PMC:7306567 / 2926-3045
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 46 | 102-111 | Chemical | denotes | ibrutinib | MESH:C551803 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T18 | 113-117 | http://purl.obolibrary.org/obo/CLO_0053799 | denotes | 4, 5 |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T9 | 102-111 | Chemical | denotes | ibrutinib | http://purl.obolibrary.org/obo/CHEBI_76612 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T22 | 0-119 | Sentence | denotes | With changing treatment modalities, new risk groups continue to emerge, such as patients treated with ibrutinib [4, 5]. |
LitCovid-PMC-OGER-BB
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T34 | 102-111 | CHEBI:76612;CHEBI:76612 | denotes | ibrutinib |
| T80755 | 102-111 | CHEBI:76612;CHEBI:76612 | denotes | ibrutinib |
2_test
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| 32572532-29437588-47963395 | 113-114 | 29437588 | denotes | 4 |
| T15892 | 113-114 | 29437588 | denotes | 4 |